Compare Deckers Outdoor Corp (DECK) vs Gilead Sciences, Inc. (GILD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Deckers Outdoor Corp vs Gilead Sciences, Inc. — how do they compare? Deckers Outdoor Corp trades at $83.02 (market cap $11.24B), while Gilead Sciences, Inc. trades at $149.28 (market cap $182.40B). The key difference: Gilead Sciences, Inc. is far larger — about 16.2× Deckers Outdoor Corp's market cap, and Gilead Sciences, Inc. pays a 2.23% dividend while Deckers Outdoor Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Deckers Outdoor Corp for 71 Days and Gilead Sciences, Inc. for 111 Days on average.
| DECK | GILD | |
|---|---|---|
Market Cap | $11.24B | $182.40B |
Volume | 3,010,945 | 4,469,821 |
Sector | Consumer Cyclical | Health |
52-Week High | $120.94 | $155.80 |
52-Week Low | $77.51 | $116.74 |
Typical Hold Time | 71 Days | 111 Days |
Enterprise Value | $10.11B | $205.46B |
Dividend Yield | — | 2.23% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Deckers (DECK) trades at $82.15, up 2.2% with neutral technical signals. The company demonstrates strong fundamentals with consistent earnings beats, 19.4% net margin, and robust revenue growth from $3.2B in 2022 to $5.0B in 2025. Recent news highlights HOKA and UGG brand momentum driving investor optimism. Technical indicators show the stock trading near resistance at $82 with support at $79.
DECK presents compelling value with a P/E of 11.7x below industry averages and analyst consensus target of $117 suggesting 43% upside. Risks include competitive pressures in footwear and potential macroeconomic headwinds affecting consumer discretionary spending. The strong cash flow generation and brand strength support continued growth potential.
Gilead Sciences (GILD) trades at $146.85, up 1.82% today, with a bullish technical signal from moving averages and recent earnings beats in Q4 2025 and Q1 2026. The company reported strong 2025 revenue of $29.44B and net income of $8.51B, though 2026 projections show a net loss. Key developments include a partnership with PAHO to expand HIV prevention drug access in Latin America, supporting long-term growth prospects amid mixed profitability metrics.
The outlook for GILD is cautiously optimistic, driven by analyst consensus favoring a buy rating (65.52%) and a price target of $151.57. Opportunities lie in HIV and oncology pipeline advancements, but risks include negative 2026 profit margins and high debt levels. Investors should weigh strong cash flow from operations against execution risks in a competitive biopharma landscape.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Deckers Outdoor Corp
Deckers Outdoor Corp designs and sells casual and performance footwear, apparel, and accessories. Primary brands include UGG, Teva, and Sanuk. The company distributes Most of its products through its wholesale business, but it also has a substantial direct-to-consumer business with its company-owned retail stores and websites. Most sales are in the United States, although the company also has retail stores and distributors throughout Europe, Asia, Canada, and Latin America. Deckers sources its products from independent manufacturers primarily in Asia.
Read more on DECK →About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →
